Jitai Technology Sees Explosive Demand Ahead of Hong Kong Debut as ‘First AI Drug Delivery Stock’
Investor appetite for AI-driven healthcare has reached a fever pitch ahead of the public listing of Jitai Technology (07666), which is positioning itself as the first company focused on AI drug delivery to list on the Hong Kong Stock Exchange.
The company’s initial public offering (IPO) has drawn overwhelming interest, with subscriptions exceeding the offering by more than 6,000 times. This surge in demand has resulted in a highly competitive allocation process, with the allotment rate for a single lot plummeting to just 0.14%.
Market sentiment has translated into significant gains in the grey market. Early trading data indicated a price jump of over 1.8 times, offering investors a profit of more than 9,000 HKD per lot. More recent figures suggest even steeper momentum, with the grey market price surging by approximately 3.2 times, pushing potential profits to 16,750 HKD per lot. This volatility underscores the intense speculation surrounding the company’s role as a pioneer in the AI-driven pharmaceutical space.
Jitai Technology is frequently grouped among the “AI drug discovery three little dragons,” a term reflecting the high growth potential and disruptive nature of the small group of AI-centric biotech firms entering the public markets. The company’s corporate leadership and board structure are now under scrutiny as the firm transitions to a public entity on May 12, 2026.
The massive oversubscription and grey market premiums highlight a broader trend of investor enthusiasm for the intersection of artificial intelligence and biotechnology, where efficiency gains in drug delivery are viewed as a critical value driver.
